Task-sharing mental health care with non-specialist providers benefits adults with psychologic distress after experiencing violence.

The Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer disease psychosis (ADP).

An in vivo assessment tool measuring negative emotion reactivity may predict future self-harm and suicidal ideation in adolescents.

Patients utilizing a self-directed CBT program experience reductions in pain interference, sleep disturbance, and depressive symptoms.

Significant productivity loss can be seen up to 15 years before early-onset dementia diagnosis, potentially explained by delays in diagnosis.

Those undergoing bariatric surgery may experience an increased risk for alcohol problems due to alterations in ethanol pharmacokinetics.

Prospectively documented childhood abuse is associated with a significantly increased long-term risk for adult migraine in men, and depression seems to partially mediate this rela ...

Adults with elevated emotional dysfunction report higher current ADHD symptoms regardless of an actual ADHD diagnosis.

The FDA has approved Leqembi Iqlik (lecanemab-irmb) subcutaneous weekly starting dose, enabling fully at-home treatment ...

The FDA accepted the NDA for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027.

The use of benzodiazepines among older adults in the US decreased and then plateaued after the COVID-19 pandemic.